drugset / Trial / NCT05628363
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Active not recruiting
28 enrolled
Washington University School of Medicine
Varian Medical Systems · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial is a prospective clinical trial designed to demonstrate the safety and feasibility of whole-pelvis adaptive prostate stereotactic body radiation therapy (SBRT) with a tumor boost to the magnetic resonance (MR)-detected sites of disease. The hypothesis is that this treatment approach will be safe and feasible with \<15% of patients experiencing an acute CTCAEv5 grade ≥3 genitourinary (GU) or gastrointestinal (GI) adverse event.
Timeline
- Start
- 2023-01-18
- Primary completion
- 2025-10-25
- Completion
- 2030-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Bicalutamide | Other / unclassified | — | — |
| Background | Degarelix | Other / unclassified | — | — |
| Background | Goserelin | Other / unclassified | — | — |
| Background | Leuprolide | Other / unclassified | — | — |
| Background | Relugolix | Small molecule | — | — |
| Background | flutamide | Small molecule | — | — |